Source: Public Filings
ENTITY
BeiGene (6160 HK)
BeiGene (6160 HK)
286
Analysis
Health Care • China
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
x